Trial Profile
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Maintenance Dosing Period to Evaluate the Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Congenital ichthyosiform erythroderma; Ichthyosis; Netherton Syndrome
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2023 Results assessing whether secukinumab, an IL-17A inhibitor, can improve ichthyosis across several congenital ichthyosis subtypes published in the Archives of Dermatological Research
- 19 Nov 2020 Status changed from active, no longer recruiting to completed.
- 06 May 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.